182 related articles for article (PubMed ID: 29702479)
1. Preparation and characterization of simvastatin/DMβCD complex and its pharmacokinetics in rats.
Gu F; Ning J; Fan H; Wu C; Wang Y
Acta Pharm; 2018 Jun; 68(2):145-157. PubMed ID: 29702479
[TBL] [Abstract][Full Text] [Related]
2. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process.
Jun SW; Kim MS; Kim JS; Park HJ; Lee S; Woo JS; Hwang SJ
Eur J Pharm Biopharm; 2007 Jun; 66(3):413-21. PubMed ID: 17240129
[TBL] [Abstract][Full Text] [Related]
3. Aurisin A Complexed with 2,6-Di-
Charoenwongpaiboon T; Oo A; Nasoontorn S; Rungrotmongkol T; Kanokmedhakul S; Mahalapbutr P
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077178
[TBL] [Abstract][Full Text] [Related]
4. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
Badr-Eldin SM; Elkheshen SA; Ghorab MM
Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
[TBL] [Abstract][Full Text] [Related]
5. Binary inclusion complexes of diflunisal with β-cyclodextrin and hydroxypropyl-β-cyclodextrin: Preparation and characterization.
Bashir M; Syed HK; Asghar S; Irfan M; Aslam N; Iqbal MS; Khan IU; Shah PA; Khan NR; Ahmad J; Saleem M; Asif M
Pak J Pharm Sci; 2020 Sep; 33(5(Supplementary)):2307-2315. PubMed ID: 33832905
[TBL] [Abstract][Full Text] [Related]
6. Preparation, physicochemical characteristics and bioavailability studies of an atorvastatin hydroxypropyl-beta-cyclodextrin complex.
Lv HX; Zhang ZH; Hui-Jiang ; Waddad AY; Zhou JP
Pharmazie; 2012 Jan; 67(1):46-53. PubMed ID: 22393830
[TBL] [Abstract][Full Text] [Related]
7. Preparation and statistical optimization of alginate based stomach specific floating microcapsules of simvastatin.
Premchandani TA; Barik BB
Acta Pol Pharm; 2012; 69(4):751-61. PubMed ID: 22876619
[TBL] [Abstract][Full Text] [Related]
8. Improvement of gliquidone hypoglycaemic effect in rats by cyclodextrin formulations.
Miro A; Quaglia F; Sorrentino U; La Rotonda MI; D'Emmanuele Di Villa Bianca R; Sorrentino R
Eur J Pharm Sci; 2004 Sep; 23(1):57-64. PubMed ID: 15324923
[TBL] [Abstract][Full Text] [Related]
9. Solubility enhancement of simvastatin: a review.
Murtaza G
Acta Pol Pharm; 2012; 69(4):581-90. PubMed ID: 22876598
[TBL] [Abstract][Full Text] [Related]
10. Preparation and characterization of inclusion complexes of prazosin hydrochloride with beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin.
Liu L; Zhu S
J Pharm Biomed Anal; 2006 Jan; 40(1):122-7. PubMed ID: 16095859
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of solid dispersion of simvastatin.
Silva TD; Arantes VT; Resende JA; Speziali NL; de Oliveira RB; Vianna-Soares CD
Drug Dev Ind Pharm; 2010 Nov; 36(11):1348-55. PubMed ID: 20545512
[TBL] [Abstract][Full Text] [Related]
12. Co-solvent evaporation method for enhancement of solubility and dissolution rate of poorly aqueous soluble drug simvastatin: in vitro-in vivo evaluation.
Pandya P; Gattani S; Jain P; Khirwal L; Surana S
AAPS PharmSciTech; 2008; 9(4):1247-52. PubMed ID: 19115110
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin-Nicotinamide Co-Crystals: Formation, Pharmaceutical Characterization and in vivo Profile.
Khan FM; Ahmad M; Idrees HA
Drug Des Devel Ther; 2020; 14():4303-4313. PubMed ID: 33116417
[TBL] [Abstract][Full Text] [Related]
14. Physicochemical and dissolution studies of simvastatin solid dispersions with Pluronic F127.
Karolewicz B; Gajda M; Owczarek A; Pluta J; Górniak A
Pharmazie; 2014 Aug; 69(8):589-94. PubMed ID: 25158569
[TBL] [Abstract][Full Text] [Related]
15. Optimization of caseinate-coated simvastatin-zein nanoparticles: improved bioavailability and modified release characteristics.
Ahmed OA; Hosny KM; Al-Sawahli MM; Fahmy UA
Drug Des Devel Ther; 2015; 9():655-62. PubMed ID: 25670883
[TBL] [Abstract][Full Text] [Related]
16. Use of cyclodextrins as solubilizing agents for simvastatin: effect of hydroxypropyl-β-cyclodextrin on lactone/hydroxyacid aqueous equilibrium.
Ungaro F; Giovino C; Catanzano O; Miro A; Mele A; Quaglia F; La Rotonda MI
Int J Pharm; 2011 Feb; 404(1-2):49-56. PubMed ID: 21056648
[TBL] [Abstract][Full Text] [Related]
17. Diloxanide furoate binary complexes with β-, methyl-β-, and hydroxypropyl-β-cyclodextrins: inclusion mode, characterization in solution and in solid state and in vitro dissolution studies.
Aloisio C; Longhi M
Pharm Dev Technol; 2018 Sep; 23(7):723-731. PubMed ID: 28758845
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of binary and ternary cyclodextrin complexes with econazole nitrate in solution and in solid state.
Jug M; Mennini N; Kövér KE; Mura P
J Pharm Biomed Anal; 2014 Mar; 91():81-91. PubMed ID: 24444785
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of ibuproxam complexation with amorphous beta-cyclodextrin derivatives in solution and in the solid state.
Mura P; Zerrouk N; Faucci M; Maestrelli F; Chemtob C
Eur J Pharm Biopharm; 2002 Sep; 54(2):181-91. PubMed ID: 12191690
[TBL] [Abstract][Full Text] [Related]
20. Characterization and in vivo evaluation of an inclusion complex of oridonin and 2-hydroxypropyl-beta-cyclodextrin.
Yan Z; Xu W; Sun J; Liu X; Zhao Y; Sun Y; Zhang T; He Z
Drug Dev Ind Pharm; 2008 Jun; 34(6):632-41. PubMed ID: 18568914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
